Explaining Marginal Benefits to Patients, When “Marginal” Means Additional but Not Necessarily Small
暂无分享,去创建一个
[1] P. Murawa,et al. Erlotinib Plus Gemcitabine Compared With Gemcitabine Alone in Patients With Advanced Pancreatic Cancer: A Phase III Trial of the National Cancer Institute of Canada Clinical Trials Group , 2023, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[2] H. Wasvary,et al. Multidisciplinary management of colorectal cancer enhances access to multimodal therapy and compliance with National Comprehensive Cancer Network (NCCN) guidelines , 2012, International Journal of Colorectal Disease.
[3] D. White,et al. A randomized trial of two methods to disclose prognosis to surrogate decision makers in intensive care units. , 2010, American journal of respiratory and critical care medicine.
[4] Thomas J. Smith,et al. Palliative Chemotherapy: When Is It Worth It and When Is It Not? , 2010, Cancer Journal.
[5] Thomas J. Smith,et al. American Society of Clinical Oncology Clinical Practice Guideline update on chemotherapy for stage IV non-small-cell lung cancer. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[6] David Hanauer,et al. Implementation of the Quality Oncology Practice Initiative at a university comprehensive cancer center. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[7] Thomas J. Smith,et al. Efficacy does not necessarily translate to cost effectiveness: a case study in the challenges associated with 21st-century cancer drug pricing. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[8] S. Payne,et al. Advanced cancer patients’ prognostic information preferences: a review , 2009, Palliative medicine.
[9] C. Daugherty,et al. What are terminally ill cancer patients told about their expected deaths? A study of cancer physicians' self-reports of prognosis disclosure. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[10] Thomas J. Smith,et al. The role of chemotherapy at the end of life: "when is enough, enough?". , 2008, JAMA.
[11] A. Abernethy,et al. Patient–oncologist communication in advanced cancer: predictors of patient perception of prognosis , 2008, Supportive Care in Cancer.
[12] R. Miksad,et al. Does a statistically significant survival benefit of erlotinib plus gemcitabine for advanced pancreatic cancer translate into clinical significance and value? , 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[13] P. Butow,et al. A systematic review of prognostic/end-of-life communication with adults in the advanced stages of a life-limiting illness: patient/caregiver preferences for the content, style, and timing of information. , 2007, Journal of pain and symptom management.
[14] K. Iwasaki,et al. Comparing hospice and nonhospice patient survival among patients who die within a three-year window. , 2007, Journal of pain and symptom management.
[15] Thomas J. Smith,et al. Why do patients choose chemotherapy near the end of life? A review of the perspective of those facing death from cancer. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[16] N. Petrelli,et al. Is it cost-effective to add erlotinib to gemcitabine in advanced pancreatic cancer? , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[17] L. Kristjanson,et al. What do patients receiving palliative care for cancer and their families want to be told? A Canadian and Australian qualitative study , 2004, BMJ : British Medical Journal.
[18] L. Fallowfield,et al. Communicating sad, bad, and difficult news in medicine , 2004, The Lancet.
[19] D. Henry,et al. Describing treatment effects to patients , 2003, Journal of General Internal Medicine.
[20] A. Handley. Do not resuscitate , 2001, Heart.
[21] J. Finkelstein,et al. Patients with advanced cancer: a survey of the understanding of their illness and expectations from palliative radiotherapy for symptomatic metastases. , 2001, Clinical oncology (Royal College of Radiologists (Great Britain)).
[22] D. V. Von Hoff,et al. Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: a randomized trial. , 1997, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[23] R. Clarnette,et al. Advance Directives Affecting Medical Treatment Choices , 1997, Journal of palliative care.
[24] T. Smith,et al. How Long does it Take to Get a “Do not Resuscitate” Order? , 1997, Journal of palliative care.
[25] D. V. Von Hoff,et al. A phase II trial of gemcitabine in patients with 5-FU-refractory pancreas cancer. , 1996, Annals of oncology : official journal of the European Society for Medical Oncology.
[26] Thomas J. Smith,et al. Outcomes of cancer treatment for technology assessment and cancer treatment guidelines. American Society of Clinical Oncology. , 1996, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[27] J. Tulsky,et al. How do medical residents discuss resuscitation with patients? , 1995, Journal of General Internal Medicine.
[28] W. Mackillop,et al. Cancer patients' perceptions of their disease and its treatment. , 1988, British Journal of Cancer.